(UroToday.com) Variation in prostate cancer incidence, mortality and outcomes between racial and ethnic groups has been wide recognized for many years. Men of African Ancestry experience the greatest burden of disease, due to a presumed interplay of socioeconomic factors, environmental exposures, and biologic/epigenetic phenomena. However, the causes underlying these differences is much less well understood. Certainly, work examining prostate cancer outcomes in equal access health care systems has demonstrated that that disparities in access to care contribute. As prostate cancer care moves to increasingly personalized care, there is an increasing recognition of the wide variation in access to care including genomic and precision medicine. In particular, men of African ancestry are underrepresented in genomic and precision medicine studies. In the Prostate, Testicular, and Penile Oral Abstract Session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Mahal presented a comprehensive analysis encompassing genomic analysis and assessment of treatment patterns to better understand disparities in advanced prostate cancer.